Target-based selection of flavonoids for neurodegenerative disorders.
Identifieur interne : 000992 ( PubMed/Checkpoint ); précédent : 000991; suivant : 000993Target-based selection of flavonoids for neurodegenerative disorders.
Auteurs : Quinton R D. Jones [Canada] ; Jordan Warford ; H P Vasantha Rupasinghe ; George S. RobertsonSource :
- Trends in pharmacological sciences [ 1873-3735 ] ; 2012.
English descriptors
- KwdEn :
- Alzheimer Disease (drug therapy), Animals, Cisplatin (toxicity), Flavonoids (chemistry), Flavonoids (pharmacokinetics), Flavonoids (pharmacology), Flavonoids (therapeutic use), Humans, Mitochondria (metabolism), Parkinson Disease (drug therapy), Reactive Oxygen Species (antagonists & inhibitors), Reactive Oxygen Species (metabolism).
- MESH :
- chemical , antagonists & inhibitors : Reactive Oxygen Species.
- chemical , chemistry : Flavonoids.
- chemical , metabolism : Reactive Oxygen Species.
- chemical , pharmacokinetics : Flavonoids.
- chemical , pharmacology : Flavonoids.
- chemical , therapeutic use : Flavonoids.
- chemical , toxicity : Cisplatin.
- drug therapy : Alzheimer Disease, Parkinson Disease.
- metabolism : Mitochondria.
- Animals, Humans.
Abstract
Habitual consumption of dietary flavonoids known to improve mitochondrial bioenergetics and inhibit various secondary sources of reactive oxygen species (ROS) reduces the risk for neurodegenerative disorders such as Parkinson's disease (PD), stroke, and Alzheimer's disease (AD). Combining specific dietary flavonoids selected on the basis of oral bioavailability, brain penetration, and the inhibition of multiple processes responsible for excessive ROS production may be a viable approach for the prevention and treatment of neurodegenerative disorders. Inclusion of flavonoids that raise cAMP levels in the brain may be of additional benefit by reducing the production of proinflammatory mediators and stimulating the transcriptional machinery necessary for mitochondrial biosynthesis. Preclinical models suggest that flavonoids reduce hearing loss resulting from treatment with the chemotherapeutic drug cisplatin by opposing the excessive production of ROS and proinflammatory mediators implicated in PD, stroke, and AD. Flavonoid combinations optimized for efficacy in models of cisplatin-induced hearing loss (CIHL) may therefore have therapeutic utility for neurodegenerative disorders.
DOI: 10.1016/j.tips.2012.08.002
PubMed: 22980637
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22980637Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Target-based selection of flavonoids for neurodegenerative disorders.</title><author><name sortKey="Jones, Quinton R D" sort="Jones, Quinton R D" uniqKey="Jones Q" first="Quinton R D" last="Jones">Quinton R D. Jones</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Faculty of Medicine, 1459 Oxford Street, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4R2.</nlm:affiliation><country>Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, 1459 Oxford Street, Dalhousie University, Halifax, Nova Scotia</wicri:regionArea><wicri:noRegion>Nova Scotia</wicri:noRegion></affiliation></author><author><name sortKey="Warford, Jordan" sort="Warford, Jordan" uniqKey="Warford J" first="Jordan" last="Warford">Jordan Warford</name></author><author><name sortKey="Rupasinghe, H P Vasantha" sort="Rupasinghe, H P Vasantha" uniqKey="Rupasinghe H" first="H P Vasantha" last="Rupasinghe">H P Vasantha Rupasinghe</name></author><author><name sortKey="Robertson, George S" sort="Robertson, George S" uniqKey="Robertson G" first="George S" last="Robertson">George S. Robertson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22980637</idno><idno type="pmid">22980637</idno><idno type="doi">10.1016/j.tips.2012.08.002</idno><idno type="wicri:Area/PubMed/Corpus">000A15</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A15</idno><idno type="wicri:Area/PubMed/Curation">000A15</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A15</idno><idno type="wicri:Area/PubMed/Checkpoint">000A15</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Target-based selection of flavonoids for neurodegenerative disorders.</title><author><name sortKey="Jones, Quinton R D" sort="Jones, Quinton R D" uniqKey="Jones Q" first="Quinton R D" last="Jones">Quinton R D. Jones</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Faculty of Medicine, 1459 Oxford Street, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4R2.</nlm:affiliation><country>Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, 1459 Oxford Street, Dalhousie University, Halifax, Nova Scotia</wicri:regionArea><wicri:noRegion>Nova Scotia</wicri:noRegion></affiliation></author><author><name sortKey="Warford, Jordan" sort="Warford, Jordan" uniqKey="Warford J" first="Jordan" last="Warford">Jordan Warford</name></author><author><name sortKey="Rupasinghe, H P Vasantha" sort="Rupasinghe, H P Vasantha" uniqKey="Rupasinghe H" first="H P Vasantha" last="Rupasinghe">H P Vasantha Rupasinghe</name></author><author><name sortKey="Robertson, George S" sort="Robertson, George S" uniqKey="Robertson G" first="George S" last="Robertson">George S. Robertson</name></author></analytic><series><title level="j">Trends in pharmacological sciences</title><idno type="eISSN">1873-3735</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (drug therapy)</term><term>Animals</term><term>Cisplatin (toxicity)</term><term>Flavonoids (chemistry)</term><term>Flavonoids (pharmacokinetics)</term><term>Flavonoids (pharmacology)</term><term>Flavonoids (therapeutic use)</term><term>Humans</term><term>Mitochondria (metabolism)</term><term>Parkinson Disease (drug therapy)</term><term>Reactive Oxygen Species (antagonists & inhibitors)</term><term>Reactive Oxygen Species (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Reactive Oxygen Species</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Flavonoids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Reactive Oxygen Species</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Flavonoids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Flavonoids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Flavonoids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Cisplatin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Alzheimer Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Mitochondria</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Habitual consumption of dietary flavonoids known to improve mitochondrial bioenergetics and inhibit various secondary sources of reactive oxygen species (ROS) reduces the risk for neurodegenerative disorders such as Parkinson's disease (PD), stroke, and Alzheimer's disease (AD). Combining specific dietary flavonoids selected on the basis of oral bioavailability, brain penetration, and the inhibition of multiple processes responsible for excessive ROS production may be a viable approach for the prevention and treatment of neurodegenerative disorders. Inclusion of flavonoids that raise cAMP levels in the brain may be of additional benefit by reducing the production of proinflammatory mediators and stimulating the transcriptional machinery necessary for mitochondrial biosynthesis. Preclinical models suggest that flavonoids reduce hearing loss resulting from treatment with the chemotherapeutic drug cisplatin by opposing the excessive production of ROS and proinflammatory mediators implicated in PD, stroke, and AD. Flavonoid combinations optimized for efficacy in models of cisplatin-induced hearing loss (CIHL) may therefore have therapeutic utility for neurodegenerative disorders.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22980637</PMID><DateCreated><Year>2012</Year><Month>10</Month><Day>26</Day></DateCreated><DateCompleted><Year>2013</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3735</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>11</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Trends in pharmacological sciences</Title><ISOAbbreviation>Trends Pharmacol. Sci.</ISOAbbreviation></Journal><ArticleTitle>Target-based selection of flavonoids for neurodegenerative disorders.</ArticleTitle><Pagination><MedlinePgn>602-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tips.2012.08.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-6147(12)00143-5</ELocationID><Abstract><AbstractText>Habitual consumption of dietary flavonoids known to improve mitochondrial bioenergetics and inhibit various secondary sources of reactive oxygen species (ROS) reduces the risk for neurodegenerative disorders such as Parkinson's disease (PD), stroke, and Alzheimer's disease (AD). Combining specific dietary flavonoids selected on the basis of oral bioavailability, brain penetration, and the inhibition of multiple processes responsible for excessive ROS production may be a viable approach for the prevention and treatment of neurodegenerative disorders. Inclusion of flavonoids that raise cAMP levels in the brain may be of additional benefit by reducing the production of proinflammatory mediators and stimulating the transcriptional machinery necessary for mitochondrial biosynthesis. Preclinical models suggest that flavonoids reduce hearing loss resulting from treatment with the chemotherapeutic drug cisplatin by opposing the excessive production of ROS and proinflammatory mediators implicated in PD, stroke, and AD. Flavonoid combinations optimized for efficacy in models of cisplatin-induced hearing loss (CIHL) may therefore have therapeutic utility for neurodegenerative disorders.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Quinton R D</ForeName><Initials>QR</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, 1459 Oxford Street, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4R2.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warford</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rupasinghe</LastName><ForeName>H P Vasantha</ForeName><Initials>HP</Initials></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>George S</ForeName><Initials>GS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Pharmacol Sci</MedlineTA><NlmUniqueID>7906158</NlmUniqueID><ISSNLinking>0165-6147</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber><NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>08</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22980637</ArticleId><ArticleId IdType="pii">S0165-6147(12)00143-5</ArticleId><ArticleId IdType="doi">10.1016/j.tips.2012.08.002</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Robertson, George S" sort="Robertson, George S" uniqKey="Robertson G" first="George S" last="Robertson">George S. Robertson</name><name sortKey="Rupasinghe, H P Vasantha" sort="Rupasinghe, H P Vasantha" uniqKey="Rupasinghe H" first="H P Vasantha" last="Rupasinghe">H P Vasantha Rupasinghe</name><name sortKey="Warford, Jordan" sort="Warford, Jordan" uniqKey="Warford J" first="Jordan" last="Warford">Jordan Warford</name></noCountry><country name="Canada"><noRegion><name sortKey="Jones, Quinton R D" sort="Jones, Quinton R D" uniqKey="Jones Q" first="Quinton R D" last="Jones">Quinton R D. Jones</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000992 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000992 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22980637
|texte= Target-based selection of flavonoids for neurodegenerative disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22980637" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |